证券代码：300015 股票简称：爱尔眼科 公告编号：2025-003 2024 年 7 月 19 日，公司召开第六届董事会第二十四次会议和第六届监事会第 十五次会议，审议通过《关于部分募投项目结项并将节余募集资金永久补充流动资 金的议案》，鉴于公司 2021 年度向特定对象发行股票募投项目中"长沙爱尔迁址扩 建项目"已达到预定可使用状态，为了提高节余募集资金的使用效率，为公司和股 东创造更大的利益，公司将该项目节余资金用于永久补充流动资金，并于募投项目 结算完毕后注销相关募集资金专项账户。本次专户注销事项完成后，相关的募集资 金三方监管协议亦予以终止。该项议案已经公司 2024 年第二次临时股东大会审议通 过。具体内容详见公司于 2024 年 7 月 20 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于部分募投项目结项并将节余募集资金永久补充流动资金的公告》（公告 编号：2024-054）。 爱尔眼科医院集团股份有限公司 （一）本次注销的部分募集资金专项账户基本情况 | 开户银行 | 银行账号 | 存续状态 | | --- | --- | --- | | 中国银行股份有限公司湖南湘江新区 ...

Core Viewpoint - Aier Eye Hospital's stock price closed at 13.19 yuan, reflecting a decline of 4.35% [1] Group 1: Stock Performance - Aier Eye Hospital reached its highest stock price of 72.27 yuan on July 1, 2021 [1] - A brokerage firm upgraded Aier Eye Hospital's rating to "Buy" on July 28, 2021, in a report titled "Aier Eye Hospital (300015): The Next Decade Opens a New Growth Curve" [1] Group 2: Dividend and Capital Increase Announcements - On June 18, 2021, Aier Eye Hospital announced a cash dividend of 1.482893 yuan per 10 shares and a capital increase of 2.965786 shares per 10 shares, with the record date on June 23, 2021, and the ex-dividend date on June 24, 2021 [1] - On July 5, 2022, Aier Eye Hospital announced a cash dividend of 1.196653 yuan per 10 shares and a capital increase of 2.991634 shares per 10 shares, with the record date on July 8, 2022, and the ex-dividend date on July 11, 2022 [1]

关于爱尔眼科医院集团股份有限公司 2024 年现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》（以下简称《保荐办法》） 等有关法律法规的要求，华泰联合证券有限责任公司作为爱尔眼科医院集团股份 有限公司（以下简称"爱尔眼科"或"公司"）向特定对象发行股票的保荐人， 于 2025 年 1 月 20 日-1 月 21 日对爱尔眼科 2024 年有关情况进行了现场检查，报 告如下： 现场检查报告 | 保荐人名称：华泰联合证券有限责任公司 被保荐公司简称：爱尔眼科 | | | --- | --- | | 保荐代表人姓名：丁明明 联系电话：010-56839300 | | | 保荐代表人姓名：高元 联系电话：025-83387686 | | | 现场检查人员姓名：丁明明、陈雪 | | | 现场检查对应期间：2024 年度 | | | 现场检查时间：2025 年 1 月 20 日-1 月 21 日 | | | 一、现场检查事项 现场检查意见 | | | （一）公司治理 是 不适用 | 否 | | 现场检查手段：察看上市公司的主要经营管理场所；查阅公司章程、公司的业务规章制度及 | | | 三会文件等；查阅公司报 ...

二、培训及交流的时间 华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 2024年度持续督导培训情况报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关规 定，华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"、"公司"）向特定对 象发行股票的保荐机构，对爱尔眼科进行持续督导。2025 年 1 月 20 日，华泰联 合证券持续督导小组完成了对爱尔眼科相关董事、监事、高级管理人员、中层管 理人员的培训工作，特向贵所报送培训工作报告。 一、培训和交流的对象 爱尔眼科相关董事、监事、高级管理人员、中层管理人员等相关人员参与本 次培训。 通过此次培训授课，爱尔眼科的董事、监事、高级管理人员、中层管理人员 等相关人员加深了对公司法以及中国证券监督管理委员会和深圳证券交易所相 关法律、法规、创业板相关业务规则以及市场违规案例的了解和认识，促使上述 保荐代表人： 2025 年 1 月 20 日，华泰联合证券持续督导小组对爱尔眼科参与培训人员以 现场 ...

Group 1 - The Guangxi Zhuang Autonomous Region Market Supervision Administration announced typical cases of false and illegal advertisements in the livelihood sector for 2024, with 336 cases identified from nearly 5 million advertisements monitored between April and December 2024 [1] - A specific case involved Guigang Aier Eye Hospital Co., Ltd., which published misleading advertisements claiming to lead in the number of myopia correction surgeries and other exaggerated statements not aligned with the approved advertising content [1] - The hospital's actions violated the Medical Advertising Management Measures, leading to administrative penalties imposed by the Guigang Market Supervision Administration in March 2024 [1] Group 2 - Aier Eye Hospital holds a 91.77% stake in Guigang Aier Eye Hospital Co., Ltd., indicating significant ownership and potential influence over its operations and compliance [2]

证券代码：300015 股票简称：爱尔眼科 公告编号：2024-096 爱尔眼科医院集团股份有限公司 关于2021年限制性股票激励计划首次授予部分第三个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次限制性股票解除限售股份上市流通时间为 2024 年 12 月 16 日； 2、本次实际符合解锁条件的激励对象共 4,582 人，申请解锁的限制性股票共计 20,000,097 股，占公司目前总股本的 0.2144%。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 6 月 14 日召 开第六届董事会第二十三次会议、第六届监事会第十四次会议，审议通过了《关于 2021 年限制性股票激励计划首次授予部分第三个解除限售期解除限售条件成就但 股票暂不上市的议案》。公司董事会认为首次授予部分第三个解除限售期可解除限 售条件已经满足，根据 2020 年年度股东大会对董事会的授权，同意公司按照《公司 2021 年限制性股票激励计划（草案）》（以下简称"本次激励计划"、"激励计划"） 的相关规定办理 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2024-095 爱尔眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或者重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）近日收到公司控股股 东爱尔医疗投资集团有限公司（以下简称"爱尔投资"）的通知，获悉爱尔投资 将持有公司的部分股份进行质押，具体事项如下： 一、股东股份质押的基本情况 | 股东 | 是否为 控股股 东或第 | | 占其所 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一大股 | 本次质押 | 持股份 | 司总 | 股份性质 | 为补 | 质押起 | 质押到期 | 质权人 | 用途 | | 名称 | | 股数（股） | | 股本 | | 充质 | 始日 | 日 | | | | | 东及其 | | 比例 | 比例 | | 押 | | | | | | | 一致行 | | | | | | | | | | | ...

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook for its stock performance relative to the market index [4][7]. Core Insights - The company reported a stable revenue of approximately 16.3 billion yuan for the first three quarters of 2024, reflecting a year-on-year growth of 1.58%. The net profit attributable to the parent company was about 3.45 billion yuan, up 8.5% year-on-year [3]. - The growth in surgical volume outpaced revenue growth, with outpatient visits increasing by 9.23% and surgical procedures by 6.92% in the first half of 2024. However, the average price per service declined year-on-year [3]. - The company is expanding its network of county hospitals and continuing its internationalization strategy, having acquired 87 medical institutions and 100% of the UK-based Optimax Group [3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company's gross margin was 51.0%, with a net profit margin of 21.2%. The gross margin for Q3 2024 was reported at 53.9%, showing a decline of 2.4 percentage points year-on-year [3]. - The company expects revenues of approximately 21.14 billion yuan in 2024, with net profits projected at 3.68 billion yuan, reflecting a price-to-earnings (PE) ratio of about 35.8x [4][6]. Growth Projections - Revenue growth is forecasted at 3.8% for 2024, with further increases to 8.8% in 2025 and 5.2% in 2026. Net profit is expected to grow by 9.6% in 2025 and 7.6% in 2026 [6][4]. - The company is anticipated to benefit from a recovering macroeconomic environment, particularly in its domestic business [3]. Strategic Developments - The company is enhancing its county hospital network and pursuing international expansion, which is expected to increase its patient coverage and operational advantages [3]. - The acquisition of Optimax Group is a significant step in entering the UK ophthalmology market, indicating a strong commitment to international growth [3].

Core Viewpoint - Aier Eye Hospital is facing serious allegations of issuing false medical certificates and engaging in commercial bribery, leading to administrative penalties from the National Health Commission [1][3][7]. Group 1: Allegations of False Medical Certificates - Reports indicate that Aier Eye Hospital has been accused of falsifying surgical dates on medical certificates, which are then provided to patients to facilitate passing health checks [2][3]. - Specific cases have emerged, such as a young man who altered the date on his medical certificate to gain employment, which later resulted in severe health consequences and subsequent legal action against the hospital [3][4]. - The National Health Commission has conducted investigations across multiple provinces, uncovering instances of false medical documentation at several Aier facilities [3]. Group 2: Commercial Bribery Issues - Allegations of commercial bribery have surfaced, with reports of Aier Eye Hospital engaging in practices that incentivize referrals from local medical practitioners [7][8]. - A case in Suqian led to the closure of a related medical institution due to bribery allegations, highlighting systemic issues within Aier's operational practices [7]. - The company has faced fines for commercial bribery, including a recent penalty of 200,000 yuan for similar offenses at a facility in Wuxi [8]. Group 3: Management and Operational Concerns - Aier Eye Hospital's management structure has been criticized for prioritizing profit over patient care, with a focus on financial metrics rather than medical outcomes [9][10]. - The company has a significant goodwill value of 8.717 billion yuan, raising concerns about potential impairment risks due to ongoing administrative penalties [9]. - Former employees have reported a culture where the CEO's directives overshadow medical judgment, leading to questionable practices in patient treatment [10]. Group 4: Patient Experiences and Complaints - Numerous patient complaints have emerged regarding unnecessary surgeries and inadequate post-operative care, with some patients alleging they were misled into undergoing procedures [13][19]. - A specific case involved a patient who experienced severe complications after a cataract surgery, raising questions about the hospital's adherence to medical standards [13][19]. - The lack of formal responses to patient complaints has been noted, with some patients feeling ignored by regulatory bodies despite repeated attempts to seek redress [20].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [2][154]. Core Insights - The company is a global leader in ophthalmic medical services, with a strong brand influence and an expanding medical network, which includes 881 hospitals and clinics worldwide as of the end of 2023 [7][20]. - The company has experienced rapid growth in both revenue and net profit, with projections for net profit reaching 38.08 billion, 42.56 billion, and 49.16 billion yuan for 2024, 2025, and 2026 respectively [7][152]. - The report highlights the increasing demand for ophthalmic services driven by a large population of myopic individuals and an aging population, which is expected to sustain growth in the ophthalmic medical market [9][54]. Summary by Sections 1. Company Overview - The company was founded in 2002 and went public in 2009, establishing itself as a professional ophthalmic chain medical institution [20]. - It has expanded internationally since 2016, with a presence in regions including mainland China, Hong Kong, Europe, the United States, and Southeast Asia [20]. 2. Market Growth - The Chinese ophthalmic medical service market is projected to grow significantly, with the refractive surgery market expected to increase from 5.9 billion yuan in 2015 to 72.5 billion yuan by 2025, reflecting a compound annual growth rate (CAGR) of 28.51% [9][74]. - The prevalence of myopia among children and adolescents is a major driver for the market, with a reported rate of 51.9% in 2022 [95]. 3. Strategic Development - The company is implementing a "1+8+N" strategic layout to enhance its tiered chain network, aiming to establish a world-class ophthalmic medical center and several regional centers across major cities [8][116]. - The number of hospitals and outpatient departments has increased significantly, with 256 hospitals and 183 outpatient departments in China as of 2023 [119]. 4. Financial Performance - The company reported a revenue of 20.37 billion yuan in 2023, with a year-on-year growth of 26.4% [10]. - The gross profit margin has remained stable around 50%, with net profit margins improving from 14.33% in 2019 to 17.95% in 2023 [47][48]. 5. Research and Innovation - The company has increased its R&D investment from 2.23 billion yuan in 2021 to 3.33 billion yuan in 2023, with a focus on enhancing its medical services and developing innovative treatment methods [129][131]. - It has achieved significant research milestones, including numerous published papers and patents, indicating a strong commitment to advancing ophthalmic care [133][139].